TIM3 Expression in Anaplastic-Thyroid-Cancer-Infiltrating Macrophages: An Emerging Immunotherapeutic Target.

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Anaplastic thyroid cancer (ATC) is an aggressive cancer with limited treatment options.
• Tumor-associated macrophages (TAMs) are abundant in ATC and linked to poor prognosis.
• Targeting immune checkpoints in TAMs is a potential therapeutic strategy for ATC.

Purpose of the Study:

• To investigate the role of the immune checkpoint TIM-3 in TAMs within ATC.
• To explore TIM-3 as a potential immunotherapeutic target for ATC.

Main Methods:

• Analysis of immune cell infiltration in ATC xenograft tumors.
• Flow cytometry to identify and phenotype macrophages (CD11b+, F4/80+).
• Assessment of M2 polarization (CD206, Arg1/iNOS ratio) and TIM-3 expression via RT-PCR, immunofluorescence, and flow cytometry.

Main Results:

• Macrophages constituted a significant portion (24-28%) of immune cells in ATC xenografts.
• Approximately 40% of these macrophages exhibited M2-like polarization.
• TIM-3 expression was detected in ATC tumors, specifically on macrophages, and correlated with macrophage markers.

Conclusions:

• TIM-3 is identified as a novel immune checkpoint expressed on macrophages in ATC.
• TIM-3's role as a negative immune regulator suggests its potential as an immunotherapeutic target for anaplastic thyroid cancer.